Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Dec;30:140-6.
doi: 10.1016/j.copbio.2014.06.012. Epub 2014 Jul 12.

Therapeutic Monoclonal Antibodies and Consistent Ends: Terminal Heterogeneity, Detection, and Impact on Quality

Affiliations
Review

Therapeutic Monoclonal Antibodies and Consistent Ends: Terminal Heterogeneity, Detection, and Impact on Quality

Kurt Brorson et al. Curr Opin Biotechnol. .

Abstract

Monoclonal antibodies (mAbs) are biological macromolecules with complex post-translational modifications that can be observed when assessing product variants. The N- and C-terminal heterogeneities of commercially produced antibodies have been observed and extensively studied over the past 30 years. This review summarizes the current literature on detectable antibody termini variants from cultured cells. The presence of these heterogeneities can be detected by many different analytical methods, mostly based on sequence, charge and size differences. Examples are presented that highlight terminal heterogeneities, methods of detection, and their impact on the quality of mAbs. Regulatory considerations are also discussed regarding the potential impact on product quality, safety, and efficacy.

Similar articles

See all similar articles

Cited by 12 articles

See all "Cited by" articles

MeSH terms

Feedback